Christopher Missling
Amministratore Delegato presso ANAVEX LIFE SCIENCES CORP.
Patrimonio netto: 5 M $ in data 30/06/2024
Profilo
Christopher U.
Missling is currently the President, CEO, Secretary & Director at Anavex Life Sciences Corp.
He previously held positions as the Chief Financial Officer at ImmunoGen, Inc., CFO & Senior Vice President-Strategic Operations at Curis, Inc., Head-Financial Planning at Aventis, Inc., and Head-Healthcare Investment Banking at Brimberg & Co. He has a graduate and doctorate degree from Ludwig-Maximilians-Universität München, an MBA from WHU-Otto Beisheim School of Management, and another MBA from Kellogg School of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 28/03/2024 | 1 250 210 ( 1.48% ) | 5 M $ | 30/06/2024 |
Posizioni attive di Christopher Missling
| Società | Posizione | Inizio |
|---|---|---|
| ANAVEX LIFE SCIENCES CORP. | Amministratore Delegato | 05/07/2013 |
Precedenti posizioni note di Christopher Missling
| Società | Posizione | Fine |
|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - |
| IMMUNOGEN, INC. | Direttore Finanziario/CFO | - |
Brimberg & Co.
 Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Corporate Officer/Principal | - |
| CURIS, INC. | Direttore Finanziario/CFO | - |
Formazione di Christopher Missling
| Ludwig-Maximilians-Universität München | Doctorate Degree |
| WHU-Otto Beisheim School of Management | Masters Business Admin |
| Kellogg School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CURIS, INC. | Health Technology |
| ANAVEX LIFE SCIENCES CORP. | Health Technology |
| Aziende private | 3 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
| Aventis, Inc. | |
Brimberg & Co.
Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Finance |
- Borsa valori
- Insiders
- Christopher Missling
